Treatment of squamous cell esophageal cancer with topotecan: An Eastern Cooperative Oncology Group Study (E2293)

Robert F. Asbury; Stuart Lipsitz; David Graham; Carla I. Falkson; Luis Baez; Al B. Benson

doi:10.1097/00000421-200002000-00013

Treatment of squamous cell esophageal cancer with topotecan: An Eastern Cooperative Oncology Group Study (E2293)

Robert F. Asbury^*, Stuart Lipsitz, David Graham, Carla I. Falkson, Luis Baez, Al B. Benson

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

Seventeen patients with enhanced measurable squamous cell carcinoma of the esophagus were treated with topotecan 1.5 mg/m² daily for 5 days repeated every 21 days. Toxicity was severe, with 1 death from myelotoxicity and 10 patients with life-threatening myelotoxicity. Severe gastrointestinal toxicity consisting of vomiting was also seen in three patients. No response was seen in any of the patients in the study. Topotecan given in this manner has no activity in squamous cell carcinoma of the esophagus.

Original language	English (US)
Pages (from-to)	45-46
Number of pages	2
Journal	American Journal of Clinical Oncology: Cancer Clinical Trials
Volume	23
Issue number	1
DOIs	https://doi.org/10.1097/00000421-200002000-00013
State	Published - Feb 2000

Keywords

Esophageal cancer
Topotecan

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/00000421-200002000-00013

Cite this

@article{8449a3f8f733402297fab2beaf027ace,

title = "Treatment of squamous cell esophageal cancer with topotecan: An Eastern Cooperative Oncology Group Study (E2293)",

abstract = "Seventeen patients with enhanced measurable squamous cell carcinoma of the esophagus were treated with topotecan 1.5 mg/m2 daily for 5 days repeated every 21 days. Toxicity was severe, with 1 death from myelotoxicity and 10 patients with life-threatening myelotoxicity. Severe gastrointestinal toxicity consisting of vomiting was also seen in three patients. No response was seen in any of the patients in the study. Topotecan given in this manner has no activity in squamous cell carcinoma of the esophagus.",

keywords = "Esophageal cancer, Topotecan",

author = "Asbury, {Robert F.} and Stuart Lipsitz and David Graham and Falkson, {Carla I.} and Luis Baez and Benson, {Al B.}",

year = "2000",

month = feb,

doi = "10.1097/00000421-200002000-00013",

language = "English (US)",

volume = "23",

pages = "45--46",

journal = "American Journal of Clinical Oncology: Cancer Clinical Trials",

issn = "0277-3732",

publisher = "Lippincott Williams and Wilkins",

number = "1",

}

TY - JOUR

T1 - Treatment of squamous cell esophageal cancer with topotecan

T2 - An Eastern Cooperative Oncology Group Study (E2293)

AU - Asbury, Robert F.

AU - Lipsitz, Stuart

AU - Graham, David

AU - Falkson, Carla I.

AU - Baez, Luis

AU - Benson, Al B.

PY - 2000/2

Y1 - 2000/2

N2 - Seventeen patients with enhanced measurable squamous cell carcinoma of the esophagus were treated with topotecan 1.5 mg/m2 daily for 5 days repeated every 21 days. Toxicity was severe, with 1 death from myelotoxicity and 10 patients with life-threatening myelotoxicity. Severe gastrointestinal toxicity consisting of vomiting was also seen in three patients. No response was seen in any of the patients in the study. Topotecan given in this manner has no activity in squamous cell carcinoma of the esophagus.

AB - Seventeen patients with enhanced measurable squamous cell carcinoma of the esophagus were treated with topotecan 1.5 mg/m2 daily for 5 days repeated every 21 days. Toxicity was severe, with 1 death from myelotoxicity and 10 patients with life-threatening myelotoxicity. Severe gastrointestinal toxicity consisting of vomiting was also seen in three patients. No response was seen in any of the patients in the study. Topotecan given in this manner has no activity in squamous cell carcinoma of the esophagus.

KW - Esophageal cancer

KW - Topotecan

UR - http://www.scopus.com/inward/record.url?scp=0034125908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034125908&partnerID=8YFLogxK

U2 - 10.1097/00000421-200002000-00013

DO - 10.1097/00000421-200002000-00013

M3 - Article

C2 - 10683076

AN - SCOPUS:0034125908

SN - 0277-3732

VL - 23

SP - 45

EP - 46

JO - American Journal of Clinical Oncology: Cancer Clinical Trials

JF - American Journal of Clinical Oncology: Cancer Clinical Trials

IS - 1

ER -

Treatment of squamous cell esophageal cancer with topotecan: An Eastern Cooperative Oncology Group Study (E2293)

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this